RxDoctor Payments Data

Kirk Bowden, DO

Pain Medicine · Mesa, AZNPI 1255592994

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (38.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Medtronic at 37.7% of the total. Reporting peaked in 2020 at $14,391 and has fallen 87.0% since, to $1,868 in 2025. Among pain medicine clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$51,059in general payments, 2019–2025

Across 717 payments — averaging $71.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$19K
  • Boston Scientific$9K
  • Abbott$7K
  • Tersera Therapeutics LLC$7K
  • Spinal Simplicity, LLC$2K
  • Vertiflex, Inc.$1K
  • plus $6K from 54 others

What the payments were for

  • Consulting fees$8,35216%
  • Speaking & faculty fees$19,47038%
  • Travel & lodging$7,41515%
  • Food & beverage$14,52328%
  • Education$1,3003%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)78$19,250
Boston Scientific229$9,373
Abbott36$6,846
Tersera Therapeutics LLC40$6,740
Spinal Simplicity, LLC4$1,623
Vertiflex, Inc.7$1,307
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC38$563
Nevro Corp.15$520
Saluda Medical Americas, Inc.21$500
Collegium Pharmaceutical, Inc.39$466
AbbVie(2 entities)23$454
Nalu Medical, Inc.14$306
Biotronik NRO, Inc.11$271
Relievant Medsystems, Inc.5$229
Protega Pharmaceutials Inc4$225
Daiichi Sankyo Inc.21$164
Scilex Pharmaceuticals Inc.10$159
Arbor Pharmaceuticals, Inc.15$153
SPR Therapeutics, Inc8$152
Stryker3$145
GRT US Holding, Inc.7$114
Averitas Pharma Inc.4$101
Novartis5$92
Teva Pharmaceuticals USA, Inc.5$88
West Therapeutics Development, LLC4$77
Saol Therapeutics Inc.1$77
Amgen3$73
Zyla Life Sciences, Inc.7$72
Zavation Medical Products, LLC3$71
Biodelivery Sciences International, Inc.4$66
Assertio Therapeutics, Inc.7$59
Lilly USA, LLC4$55
AstraZeneca4$47
Redhill Biopharma Inc.3$44
Shionogi Inc3$42
Pfizer2$40
Ferring Pharmaceuticals Inc.2$30
Azurity Pharmaceuticals, Inc.2$29
Johnson & Johnson(2 entities)2$29
Foundation Fusion Solutions, LLC2$28
Painteq LLC1$27
Convatec Inc.1$24
Bioventus LLC1$23
MML US, Inc.1$22
Stratus Medical, LLC2$21
Springworks Therapeutics, Inc.1$21
Pacira Pharmaceuticals Incorporated1$20
Orthogenrx Inc.1$20
Vertos Medical, Inc.1$20
Hikma Pharmaceuticals USA1$19
Fidia Pharma USA Inc.1$18
Tonix Medicines, Inc.1$18
Merz Pharmaceuticals, LLC1$17
Avanos Medical1$17
Vertex1$16
International Rehabilitative Sciences, Inc1$15
Biohaven Pharmaceuticals, Inc.1$15
Piramal Critical Care1$14
Sentynl Therapeutics, Inc.1$14
Forte Bio-pharma LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,059 in reported general payments places this provider in the 90th percentile of 180 pain medicine providers in Arizona.

See all pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$528,387
Medicare patients
750
Services billed
2,853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate14$16,043
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$3,688
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen131$3,154
Buprenorphine11$2,993
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen178$2,598
Oxycodone Hcl135$2,461
Gabapentin102$1,944
Pregabalin61$1,310
Celecoxib62$1,183
Morphine Sulfate ErMorphine Sulfate45$865
Tramadol Hcl137$826
Fentanyl11$739
Hydromorphone Hcl31$562
Tizanidine Hcl48$411
Methocarbamol28$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$466$16,04314 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine$19$6,68122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 180 pain medicine providers in Arizona.

Other pain medicine in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →